Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.9520
-0.0180 (-1.86%)
At close: Dec 26, 2025, 4:00 PM EST
0.9680
+0.0160 (1.68%)
After-hours: Dec 26, 2025, 6:51 PM EST
Oncolytics Biotech Market Cap
Oncolytics Biotech has a market cap or net worth of $102.44 million as of December 26, 2025. Its market cap has increased by 54.75% in one year.
Market Cap
102.44M
Enterprise Value
94.17M
1-Year Change
54.75%
Ranking
Category
Stock Price
$0.95
Market Cap Chart
Since September 30, 2002, Oncolytics Biotech's market cap has increased from $30.90M to $102.44M, an increase of 231.53%. That is a compound annual growth rate of 5.29%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 26, 2025 | 98.70M | 40.20% |
| Dec 31, 2024 | 70.40M | -25.27% |
| Dec 29, 2023 | 94.20M | -0.95% |
| Dec 30, 2022 | 95.10M | 24.48% |
| Dec 31, 2021 | 76.40M | -24.21% |
| Dec 31, 2020 | 100.80M | -15.44% |
| Dec 31, 2019 | 119.20M | 341.48% |
| Dec 31, 2018 | 27.00M | -60.93% |
| Dec 29, 2017 | 69.10M | 178.63% |
| Dec 30, 2016 | 24.80M | -1.59% |
| Dec 31, 2015 | 25.20M | -43.88% |
| Dec 31, 2014 | 44.90M | -62.24% |
| Dec 31, 2013 | 118.90M | -57.43% |
| Dec 31, 2012 | 279.30M | 5.40% |
| Dec 30, 2011 | 265.00M | -35.74% |
| Dec 31, 2010 | 412.40M | 260.49% |
| Dec 31, 2009 | 114.40M | 129.72% |
| Dec 31, 2008 | 49.80M | -20.70% |
| Dec 31, 2007 | 62.80M | -17.04% |
| Dec 29, 2006 | 75.70M | -49.09% |
| Dec 30, 2005 | 148.70M | 19.06% |
| Dec 31, 2004 | 124.90M | 47.81% |
| Dec 31, 2003 | 84.50M | 194.43% |
| Dec 31, 2002 | 28.70M | -7.12% |
| Sep 30, 2002 | 30.90M | - |
View and export this data all the way back to 2002. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 965.00B |
| Johnson & Johnson | 500.24B |
| AbbVie | 406.46B |
| UnitedHealth Group | 300.58B |
| AstraZeneca | 286.29B |
| Novartis AG | 267.64B |
| Merck & Co. | 265.03B |
| Novo Nordisk | 232.28B |